| Literature DB >> 22453061 |
David G Levitt, Michael D Levitt.
Abstract
Although the factors involved in cirrhotic ascites have been studied for a century, a number of observations are not understood, including the action of diuretics in the treatment of ascites and the ability of the plasma-ascitic albumin gradient to diagnose portal hypertension. This communication presents an explanation of ascites based solely on pathophysiological alterations within the peritoneal cavity. A quantitative model is described based on experimental vascular and intraperitoneal pressures, lymph flow, and peritoneal space compliance. The model's predictions accurately mimic clinical observations in ascites, including the magnitude and time course of changes observed following paracentesis or diuretic therapy.Entities:
Mesh:
Year: 2012 PMID: 22453061 PMCID: PMC3361476 DOI: 10.1186/1471-230X-12-26
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Figure 1Schematic diagram of the peritoneal space. The "intestine" represents all non-hepatic, intraperitoneal organs (including the mesentery). The symbols P and Π indicate the hydrostatic and colloid osmotic pressure of the different compartments. See "Notation" for a definition of all the terms.
Hemodynamic responses to drugs in cirrhotic patients
| Drug | Δt | CO | HBF | PRA | Wedge | Free | PHVPG | Resistance | Δ(PL - PA) | Comments | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spironolactone | ||||||||||||||||||
| [ | 1440 | 8.6 | 7.3 | 1.33 | 1.24 | 3.5 | 1.8 | 23.9 | 20.8 | 6.4 | 5.5 | 17.6 | 15.3 | 13.2 | 12.3 | 2.0 | 1.15 | No ascites |
| [ | 168 | 6.75 | NR | NR | NR | 26.3 | 23.5 | 9.8 | 10.6 | 16.5 | 12.9 | NR | NR | 1.0 | 1.8 | 70% ascites | ||
| [ | 672 | 6.48 | 5.76 | 1.00 | 1.00 | NR | 18.7 | 15.7 | 2.2 | 2.8 | 16.5 | 12.9 | 16.5 | 12.9 | 1.2 | 1.8 | No ascites | |
| [ | 1344 | 5.5 | 4.9 | 1.0 | 0.94 | NR | 22.4 | 20.1 | 4.9 | 4.4 | 17.5 | 15.7 | 17.5 | 16.7 | 1.4 | 0.9 | No ascites, unrestricted Na+ | |
| Furosemide | ||||||||||||||||||
| [ | 672 | 8.4 | 6.78 | 1.29 | 1.08 | NR | 17.6 | 16.7 | 3.9 | 3.1 | 13.7 | 13.6 | 10.6 | 12.5 | 0.85 | 0.05 | No ascites | |
| [ | 1 | 6.6 | 5.5 | 1.49 | 0.82 | 5 | 3 | 31.1 | 27.7 | 9.0 | 8.2 | 22.1 | 19.5 | 14.8 | 23.8 | 2.1 | 1.3 | Acute affect, 60% ascites |
| Propranolol | ||||||||||||||||||
| [ | 1 | 7.6 | 5.9 | 1.06 | 0.862 | 3.7 | 5.5 | 23.8 | 22.9 | 5.7 | 7.0 | 18.1 | 15.9 | 17.1 | 18.4 | -0.2 | 1.1 | Varices and/or ascites |
| [ | 240 | 8.13 | 5.36 | 1.5 | 1.8 | NR | 29.7 | 26.9 | 8.6 | 10.1 | 21.1 | 16.8 | 14.1 | 9.3 | 0.65 | 2.15 | 45% ascites | |
| [ | 672 | 6.05 | 5.0 | 0.93 | 0.826 | 1.9 | 1.1 | 19.3 | 14.5 | 3.6 | 3.2 | 15.1 | 11.4 | 16.2 | 13.8 | 2.6 | 1.85 | No ascites |
| [ | 1/4 | 6.33 | 5.01 | NR | NR | 27.9 | 25.7 | 7.0 | 8.0 | 20.9 | 17.7 | NR | NR | 0.6 | 1.6 | Mild--6% ascites | ||
| [ | 1/4 | 7.17 | 5.76 | NR | NR | 31.3 | 29.2 | 7.1 | 8.4 | 24.2 | 20.8 | NR | NR | 0.4 | 1.7 | Moderate--72% ascites | ||
| [ | 1/4 | 9.03 | 5.92 | NR | NR | 32.1 | 29.6 | 8.8 | 9.5 | 23.4 | 20.1 | NR | NR | 0.9 | 1.65 | Severe--100% ascites | ||
| [ | 1848 | 7.6 | 5.8 | 1.25 | 1.01 | 5.8 | 6.4 | 28.8 | 25.9 | 8.5 | 8.3 | 20.3 | 17.6 | 16.2 | 17.4 | 1.55 | 1.35 | Varices, PHVPG> 12 |
| [ | 2160 | NR | NR | NR | 27.5 | 26.0 | 10.0 | 13.9 | 17.3 | 12.1 | NR | NR | -1.2 | 2.6 | 100% variceal bleed | |||
| [ | 336 | NR | NR | 8.8 | 12.2 | 34.5 | 32.7 | 15.8 | 17.1 | 18.7 | 15.45 | NR | NR | 0.25 | 1.63 | 75% ascites | ||
| Timolol | ||||||||||||||||||
| [ | 1 | NR | NR | NR | 24.9 | 23.6 | 8.4 | 10.0 | 16.5 | 14.4 | NR | NR | -0.15 | 1.05 | 100% varices | |||
| Carvedilol | ||||||||||||||||||
| [ | 1848 | 7.5 | 6.4 | 1.39 | 1.28 | 4.6 | 5.5 | 26.4 | 23.5 | 7.3 | 8.2 | 19.0 | 15.2 | 13.7 | 11.9 | 1.0 | 1.9 | Varices, PHVPG> 12 |
| Clonidine | ||||||||||||||||||
| [ | 168 | 6.41 | 5.40 | 1.05 | 1.33 | 5.2 | 3.4 | 30.4 | 27.4 | 10.2 | 9.7 | 20.1 | 17.6 | 19.1 | 13.2 | 1.75 | 1.25 | 100% Ascites |
| [ | 3/4 | 6.40 | 5.36 | 0.96 | 1.22 | NR | 31.3 | 28 | 11.0 | 11.4 | 20.3 | 16.6 | 21.1 | 13.6 | 1.45 | 1.85 | 100% Ascites | |
| [ | 448 | 7.8 | 6.7 | 1.2 | 1.1 | 2.6 | 4.2 | 23.9 | 24.6 | 5.1 | 8.7 | 18.8 | 15.9 | 15.7 | 14.4 | -2.15 | 1.45 | 40% ascites |
| Nitroglycerin | ||||||||||||||||||
| [ | ≈1/10 | NR | NR | NR | 22.5 | 18.9 | 4.6 | 3.6 | 17.9 | 15.1 | NR | NR | 2.3 | 1/4 | Sublingual | |||
| [ | 1 | NR | 0.93 | 0.919 | NR | 26.0 | 22.1 | 8.4 | 8.6 | 17.6 | 13.6 | NR | NR | 1.85 | 2 | Transdermal | ||
| [ | 1/3 | 7.42 | 6.75 | 1.34 | 1.1 | 6.1 | 4.0 | 29.2 | 29.3 | 8.3 | 8.2 | 20.9 | 21.1 | 15.7 | 14.4 | 0 | 00.1 | Low dose IV, 53% ascites |
| Vasopressin | ||||||||||||||||||
| [ | 1/2 | NR | NR | NR | 28.6 | 24.0 | 5.7 | 6.3 | 22.9 | 17.7 | NR | NR | 2.0 | 2.6 | Bleeding varices, 40% ascites | |||
| [ | 1/2 | 7.6 | 6.5 | 1.89 | 1.06 | 5.0 | 7.5 | 26.6 | 23.6 | 7.6 | 9.1 | 19.0 | 14.6 | 10.1 | 13.8 | 0.75 | 2.2 | 30 min IV inf |
| [ | 1/2 | 7.14 | 5.77 | 1.35 | 0.91 | NR | 17.8 | 12.7 | 6.7 | 7.3 | 11.1 | 5.4 | 8.22 | 5.93 | 2.25 | 2.85 | 40% ascites, IV inf | |
| Terlipressin | ||||||||||||||||||
| [ | 1 | NR | NR | NR | NR | 5.2 | 9 | 25.4 | 25.0 | 6.0 | 8.1 | 19.4 | 16.8 | NR | NR | -0.85 | 1.3 | Variceal gradient reduction |
| Captopril | ||||||||||||||||||
| [ | 504 | NR | NR | NR | 22.9 | 20.7 | 15.0 | 12.1 | 7.58 | 9.32 | NR | NR | 2.55 | -0.5 | 100% ascites | |||
| [ | 2160 | NR | NR | NR | 24.8 | 21.1 | 9.3 | 7.1 | 15.6 | 13.0 | NR | NR | 2.95 | 1.3 | 100% variceal bleed | |||
| Enalaprilat | ||||||||||||||||||
| [ | 1/2 | 6.7 | 6.9 | NR | NR | 32.1 | 25.6 | 11.2 | 10.8 | 21.0 | 16.1 | NR | NR | 3.45 | 2.45 | IV infusion | ||
| Losartan | ||||||||||||||||||
| [ | 336 | NR | NR | 8.4 | 8.55 | 32.4 | 28.31 | 13.21 | 14.26 | 19.21 | 14.15 | NR | NR | 1.53 | 2.53 | 63% ascites | ||
| [ | 5.8 | 5.7 | NR | NR | 20.3 | 17.3 | 4.9 | 3.7 | 15.4 | 13.6 | NR | NR | 2.1 | 0.9 | Pre-ascitic, 4 week | |||
| Saralasin | ||||||||||||||||||
| [ | ≈1/2 | 6.5 | 5.97 | 1.42 | 1.35 | 4.8 | 4.3 | 28 | 24.0 | 10.8 | 10.2 | 17.2 | 13.78 | 12.1 | 10.2 | 2.31 | 1.71 | 100% ascites, IV inf |
| Somatostatin | ||||||||||||||||||
| [ | 1/2 | 6.59 | 6.38 | 3.7 | 1.1 | 0.89 | 4.1 | 19.5 | 16.2 | 7.2 | 7.6 | 12.3 | 8.6 | 3.32 | 7.82 | 1.45 | 1.85 | 40% ascites, IV inf |
| Fenoldopam | ||||||||||||||||||
| [ | 1 | 8.9 | 10.5 | 1.5 | 1.6 | 6.1 | 4.4 | 24.6 | 28.0 | 9.2 | 8.7 | 15.4 | 19.3 | 10.23 | 12.1 | -1.45 | -1.95 | MAP: 84.6-61.8 decrease |
Δt = time interval pre--post (hours), CO = cardiac output (liters/min), HBF = hepatic blood flow (liters/min), PRA = right atrial pressure (mm Hg),
Wedge = portal wedge pressure (mm Hg), Free = free portal pressure (mm Hg), PHVPG = Wedge - Free, Resistance = hepatic flow resistance = Gradient/HBF (mm Hg/liter),
Δ(PL - PA) = change in pressure difference across the liver capsule--(pre - post), MAP = mean arterial pressure
Figure 2The model prediction for the steady state ascites volume (top), colloid osmotic pressure (middle) and lymph flow (bottom) as a function of the hepatic vein pressure gradient (P.
Figure 3Decrease in the ascites volume from the untreated case (black line) produced .
Figure 4Change in the ascites volume from the untreated case (black line) produced by a decrease in P.
Figure 5Change in the ascites volume from the untreated case (black line) produced by reduction of either P.
Figure 6Ascites volume as a function of P.
Figure 7Time dependent change in ascites volume. At time 0, the PHVPG is raised to 20 mm Hg and PRA is raised to 5 mm Hg. After a steady state is reached at 30 days, PHVPG is reduced by 20% to 16 mm Hg and PRA is lowered to 2 mm Hg.
Figure 8Time dependent change in ascites volume. At time 0, the PHVPG is raised to 16 mm Hg and PRA is raised to 5 mm Hg. After a steady state is reached at 30 days, PHVPG is reduced by 20% to 12.8 mm Hg and PRA is lowered to 2 mm Hg.
Figure 9Time dependent change in ascites volume. At time 0, the PHVPG is raised to 20 mm Hg and PRA is raised to 5 mm Hg. After a steady state is reached at 30 days, 5.3 liters of ascites fluid is removed over a period of 12 hours and, over the next 10 days, the ascites reforms.